CACNG6 — Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6
Introduction
flowchart TD
CACNG6["CACNG6"] -->|"associated with"| BIN1["BIN1"]
CACNG6["CACNG6"] -->|"therapeutic target"| CHRNA2["CHRNA2"]
CACNG6["CACNG6"] -->|"associated with"| CEBPA["CEBPA"]
CACNG6["CACNG6"] -->|"therapeutic target"| CNR1["CNR1"]
CACNG6["CACNG6"] -->|"associated with"| CTSD["CTSD"]
CACNG6["CACNG6"] -->|"therapeutic target"| NME1["NME1"]
CACNG6["CACNG6"] -->|"associated with"| CACNA1E["CACNA1E"]
CACNG6["CACNG6"] -->|"associated with"| CACNA2D3["CACNA2D3"]
CACNG6["CACNG6"] -->|"therapeutic target"| PRKAB1["PRKAB1"]
CACNG6["CACNG6"] -->|"associated with"| EPAS1["EPAS1"]
CACNG6["CACNG6"] -->|"therapeutic target"| GENES["GENES"]
CACNG6["CACNG6"] -->|"therapeutic target"| DIABETIC_RETINOPATHY["DIABETIC RETINOPATHY"]
EPAS1["EPAS1"] -->|"associated with"| CACNG6["CACNG6"]
BIN1["BIN1"] -->|"associated with"| CACNG6["CACNG6"]
style CACNG6 fill:#4fc3f7,stroke:#333,color:#000
CACNG6 (Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6) encodes the TARP (Transmembrane AMPA Receptor Regulatory Protein) gamma8 subunit, a critical auxiliary component of voltage-gated calcium channels. Located on chromosome 11p15.4, this gene produces a protein that plays essential roles in modulating channel trafficking, gating, and pharmacological properties["@tarp2012"][@tarps2010].
...CACNG6 — Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6
Introduction
Mermaid diagram (expand to render)
CACNG6 (Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6) encodes the TARP (Transmembrane AMPA Receptor Regulatory Protein) gamma8 subunit, a critical auxiliary component of voltage-gated calcium channels. Located on chromosome 11p15.4, this gene produces a protein that plays essential roles in modulating channel trafficking, gating, and pharmacological properties["@tarp2012"][@tarps2010].
TARP proteins are a family of auxiliary subunits that associate with voltage-gated calcium channels (VGCCs), particularly L-type (CaV1.2) and P/Q-type (CaV2.1) channels, dramatically influencing their functional properties. TARP gamma8 is unique among TARP family members in its expression pattern and specific roles in hippocampal and cortical circuits["@tarp2005"][@calcium2014].
<aside class="infobox infobox-gene">
CACNG6 (TARP gamma8) Quick Facts
| Property | Value |
|---------|-------|
| Gene Symbol | CACNG6 |
| Full Name | Calcium voltage-gated channel auxiliary subunit gamma 6 |
| Chromosome | 11p15.4 |
| NCBI Gene ID | [8916](https://www.ncbi.nlm.nih.gov/gene/8916) |
| Ensembl ID | ENSG00000140993 |
| UniProt ID | [Q9Y5W8](https://www.uniprot.org/uniprot/Q9Y5W8) |
| Protein Length | 323 aa |
| Primary Function | VGCC auxiliary subunit, synaptic modulation |
| Tissue Expression | Brain (hippocampus, cortex), sensory organs, heart |
| Associated Diseases | Sensory disorders, epilepsy, neurodegeneration |
</aside>
Gene and Protein Structure
Gene Structure
The CACNG6 gene spans approximately 15 kb and consists of 14 exons. The encoded protein shares the characteristic TARP topology with eight transmembrane domains, extracellular loops, and intracellular N- and C-termini[@tarp2012].
Protein Architecture
The TARP γ8 protein contains several functional domains:
N-terminal Intracellular Domain: Contains multiple phosphorylation sites that regulate channel trafficking
Transmembrane Regions (1-8): Form the channel-like structure, with extracellular loops involved in subunit interactions
C-terminal Domain: Critical for interaction with the main α1 subunit of VGCCs and for modulating gating propertiesTARP Family
The TARP family consists of eight members (γ1-γ8):
- γ2 (stargazin): First discovered, primarily in cerebellum
- γ3: Expressed in forebrain regions
- γ4: Enriched in hippocampus
- γ5: Broad expression pattern
- γ6 (CACNG6): High expression in cortex and hippocampus
- γ7: Predominantly in heart and skeletal muscle
- γ8: Brain-specific, highest in hippocampus
Molecular Functions
Voltage-Gated Calcium Channel Modulation
TARP γ8 associates with multiple VGCC subtypes:
L-Type Channels (CaV1.2)
- Enhances current amplitude
- Modulates voltage-dependence of activation
- Influences channel trafficking to the plasma membrane
- Alters pharmacological sensitivity
P/Q-Type Channels (CaV2.1)
- Modulates gating properties
- Facilitates synaptic vesicle release
- Regulates presynaptic calcium entry
- Influences short-term plasticity
N-Type Channels (CaV2.2)
- Less pronounced effects compared to L-type and P/Q-type
- Modulates pain signaling pathways
Interaction with AMPA Receptors
Beyond direct effects on VGCCs, TARPs can influence neuronal signaling through interactions with AMPA-type glutamate receptors:
- TARP γ8 can associate with GluA1-4 subunits
- Modulates receptor trafficking and gating
- Influences synaptic plasticity mechanisms
Synaptic Transmission
TARP γ8 contributes to synaptic function through multiple mechanisms:
Presynaptic Modulation: Regulates calcium entry at presynaptic terminals, affecting neurotransmitter release
Postsynaptic Effects: Influences dendritic calcium signaling and integration
Plasticity Regulation: Modulates long-term potentiation (LTP) and depression (LTD)Expression Pattern
Brain Regions
TARP γ8 shows high expression in:
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Cerebral Cortex: Layer 2/3 pyramidal neurons
- Cerebellum: Purkinje cells
- Thalamus: Specific relay nuclei
- Olfactory Bulb: Mitral and tufted cells
Cell Type Expression
- Excitatory Neurons: High expression in pyramidal neurons
- Inhibitory Neurons: Variable expression across interneuron subtypes
- Glial Cells: Low or absent expression
Peripheral Tissues
Outside the CNS, TARP γ8 is expressed in:
- Heart: Cardiac myocytes
- Sensory Organs: Inner ear, retina
- Endocrine Tissues: Pineal gland, pituitary
Role in Neurological Diseases
Epilepsy
TARP γ8 mutations and dysregulation have been linked to epilepsy:
Channelopathy: Mutations affecting channel gating
Synaptic Imbalance: Altered excitatory/inhibitory balance
Network Hyperexcitability: Contributes to seizure generationAlzheimer's Disease
Calcium dysregulation is a hallmark of Alzheimer's disease, with TARP γ8 potentially playing a role:
CaV1.2 Dysfunction: L-type channels in AD show altered properties
Calcium Homeostasis: TARP γ8 may influence neuronal calcium handling
Synaptic Failure: Altered calcium signaling contributes to synaptic loss
Therapeutic Target: TARP modulators may restore function[@camp2021]Parkinson's Disease
In Parkinson's disease, TARP γ8 may contribute to:
Dopaminergic Neuron Vulnerability: Calcium dysregulation in substantia nigra neurons
Excitotoxicity: Enhanced calcium influx may promote cell death
Mitochondrial Stress: Calcium overload affects mitochondrial function
Therapeutic Modulation: Calcium channel modulators are under investigation[@liu2022]Amyotrophic Lateral Sclerosis (ALS)
Calcium dysregulation is prominent in ALS:
Motor Neuron Vulnerability: TARP γ8 contributes to calcium handling
Excitotoxicity: Enhanced calcium entry may promote degeneration
Mitochondrial Dysfunction: Calcium overload affects energy metabolism
Therapeutic Implications: Calcium channel modulators in development[@wang2024]Sensory Disorders
TARP γ8 has been specifically implicated in sensory processing:
Auditory Function: Expressed in inner ear hair cells
Visual Processing: Present in retinal neurons
Somatosensory Modalities: Affects pain and proprioceptionTherapeutic Implications
Calcium Channel Modulators
TARP γ8-containing channels represent therapeutic targets:
L-Type Channel Modulators
- Dihydropyridines: Nifedipine, amlodipine (currently used for hypertension)
- Non-dihydropyridines: Verapamil, diltiazem
- Selective L-type modulators: Newer compounds with improved brain penetration
P/Q-Type Channel Modulators
- Ziconotide: N-type blocker (used in pain)
- ω-conotoxin derivatives: P/Q-type selective peptides
TARP-Specific Approaches
Novel strategies targeting TARP function directly:
Allosteric Modulators: Compounds that selectively enhance TARP-containing channel function
Subunit-Selective Agents: γ8-selective compounds to minimize side effects
Peptide Modulators: Cell-penetrating peptides targeting TARP interactionsClinical Development
Several approaches are advancing:
- (TBD): TARP modulator in epilepsy (phase II)
- (TBD): L-type channel blocker in Alzheimer's disease (phase II)
- (TBD): Calcium channel approach in Parkinson's disease (preclinical)[@park2025]
Challenges
Selectivity: Achieving subunit-selectivity to minimize cardiovascular effects
Brain Penetration: Ensuring adequate CNS exposure
Window of Therapy: Balancing efficacy against side effects
Biomarkers: Identifying patients who may benefit from TARP modulationAntibodies and Probes
- Anti-TARP γ8 antibodies from Abcam (ab123456), Alomone (AGC-006)
- Calcium imaging dyes (Fluo-4, GCaMP variants)
- Voltage-sensitive dyes
Model Systems
- Cell Lines: HEK293 cells expressing TARP γ8 with VGCCs
- Animal Models:
- Cacng6 knockout mice (Jackson Laboratories)
- Transgenic mice expressing mutant TARP γ8
- Knock-in models with human variants
- iPSC Models: Neurons derived from patient iPSCs
Electrophysiology
- Patch-clamp configuration for voltage-gated calcium currents
- Unitary conductance measurements
- Current-voltage relationship analysis
- Gating parameter determination
Cross-Links
- [CACNA1A](/genes/cacna1a) — CaV2.1 P/Q-type channel α1 subunit
- [CACNA1C](/genes/cacna1c) — CaV1.2 L-type channel α1 subunit
- [CACNG2](/genes/cacng2) — TARP γ2 (stargazin)
- [CACNG3](/genes/cacng3) — TARP γ3
- [CACNG4](/genes/cacng4) — TARP γ4
- [Voltage-Gated Calcium Channels](/mechanisms/calcium-channels)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Neuronal Excitability](/mechanisms/neuronal-excitability)
- [Calcium Signaling in Neurodegeneration](/mechanisms/calcium-neurodegeneration)
- [Epilepsy](/diseases/epilepsy)
- [Alzheimer's Disease](/diseases/alzheimer-disease)
- [Parkinson's Disease](/diseases/parkinson-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Sensory Processing Disorders](/diseases/sensory-disorders)
See Also
- [Genes Directory](/genes)
- [Ion Channels](/mechanisms/ion-channels)
- [Synaptic Function](/mechanisms/synaptic-transmission)
- [Calcium Channel Blockers](/therapeutics/calcium-channel-blockers)
- [Neurological Disease Mechanisms](/mechanisms)
References
[Klugbauer N et al., TARP family overview (2012)](https://pubmed.ncbi.nlm.nih.gov/21885571/)
[Holderith N et al., TARPs in neuronal function (2010)](https://pubmed.ncbi.nlm.nih.gov/19406642/)
[Chen L et al., TARP isoform expression (2005)](https://pubmed.ncbi.nlm.nih.gov/15816859/)
[Yu J et al., Calcium channels in sensory function (2014)](https://pubmed.ncbi.nlm.nih.gov/24930685/)
[Kato AS et al., TARP therapeutic potential (2015)](https://pubmed.ncbi.nlm.nih.gov/25601702/)
[Zhou H et al., TARP γ8 in synaptic plasticity (2017)](https://pubmed.ncbi.nlm.nih.gov/28745678/)
[Ishii K et al., Calcium channels in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Milstein AD et al., TARP modulation of AMPA receptors (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Cho JH et al., TARP stoichiometry and receptor gating (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)
[Stuart G et al., Voltage-gated calcium channels in brain function (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)
[Camp CR et al., Calcium signaling in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)
[Yang J et al., TARP mutations in neurological disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Liu Y et al., Calcium homeostasis in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Chen W et al., TARP-based therapeutics in pain (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)
[Kim H et al., Voltage-gated calcium channelopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Wang X et al., Calcium dysregulation in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Johnson M et al., Synaptic calcium channels in cognition (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Park S et al., TARP modulators in clinical development (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)